To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Three doses of 15mg/kg IV TXA reduces blood loss vs. placebo in trochanteric fracture surgery

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
May 2019

Three doses of 15mg/kg IV TXA reduces blood loss vs. placebo in trochanteric fracture surgery

Vol: 8| Issue: 5| Number:23| ISSN#: 2564-2537
Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A

Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial

Hong Kong Med J. 2019 Apr;25(2):120-126.

Contributing Authors:
M Li X Zhu F Chen Z Jiang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

176 patients with trochanteric fractures and scheduled for surgical treatment were randomized to receive 3 doses of intravenous tranexamic acid or placebo (normal saline). Outcomes of interest included peri-operative, obivous and hidden blood loss, post-operative hemoglobin levels, proportion of patients who received red blood cell transfusion, number of transfused red blood cell units per person,...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue